Abeona Therapeutics (NASDAQ:ABEO) Receives New Coverage from Analysts at Cantor Fitzgerald

Share on StockTwits

Analysts at Cantor Fitzgerald began coverage on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research report issued on Tuesday, FinViz reports. The brokerage set a “hold” rating and a $4.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would suggest a potential downside of 0.50% from the company’s current price.

ABEO has been the subject of several other reports. Mizuho reiterated a “hold” rating and set a $4.00 price target on shares of Abeona Therapeutics in a research report on Tuesday. ValuEngine upgraded Abeona Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, December 3rd. Zacks Investment Research cut Abeona Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 15th. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Abeona Therapeutics in a research report on Wednesday, November 20th. Finally, Maxim Group cut Abeona Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 15th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $8.30.

Shares of ABEO stock opened at $4.02 on Tuesday. The stock has a 50 day moving average of $2.73 and a 200 day moving average of $3.28. The company has a current ratio of 2.45, a quick ratio of 2.45 and a debt-to-equity ratio of 0.07. The stock has a market cap of $167.79 million, a P/E ratio of -3.38 and a beta of 2.24. Abeona Therapeutics has a twelve month low of $1.46 and a twelve month high of $8.60.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.09. On average, research analysts predict that Abeona Therapeutics will post -1.55 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC increased its position in shares of Abeona Therapeutics by 434.6% in the second quarter. Tower Research Capital LLC TRC now owns 8,719 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 7,088 shares in the last quarter. Ellington Management Group LLC purchased a new stake in shares of Abeona Therapeutics in the second quarter valued at approximately $50,000. Trexquant Investment LP purchased a new stake in shares of Abeona Therapeutics in the second quarter valued at approximately $53,000. D. E. Shaw & Co. Inc. purchased a new stake in shares of Abeona Therapeutics in the second quarter valued at approximately $59,000. Finally, Marshall Wace LLP increased its position in shares of Abeona Therapeutics by 45.9% in the second quarter. Marshall Wace LLP now owns 13,254 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 4,168 shares in the last quarter. Institutional investors and hedge funds own 55.85% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Featured Article: Put Option

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

ValuEngine Downgrades Stanley Black & Decker  to Sell
ValuEngine Downgrades Stanley Black & Decker to Sell
Santander Consumer USA  Upgraded to Hold at Zacks Investment Research
Santander Consumer USA Upgraded to Hold at Zacks Investment Research
Redwood Trust  Rating Lowered to Hold at Zacks Investment Research
Redwood Trust Rating Lowered to Hold at Zacks Investment Research
RingCentral  Upgraded by Goldman Sachs Group to Buy
RingCentral Upgraded by Goldman Sachs Group to Buy
Regions Financial  Rating Increased to Buy at Janney Montgomery Scott
Regions Financial Rating Increased to Buy at Janney Montgomery Scott
Learning Technologies Group PLC  Given Consensus Recommendation of “Buy” by Analysts
Learning Technologies Group PLC Given Consensus Recommendation of “Buy” by Analysts


© 2006-2020 Ticker Report